Tesamorelin is a synthetic 44-amino acid analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus that stabilizes the peptide against dipeptidyl peptidase-IV (DPP-IV) enzymatic degradation. This structural modification extends its plasma half-life while preserving full binding affinity and agonist activity at the GHRH receptor. Tesamorelin has been studied in both preclinical models and clinical research settings for its effects on GH secretion and downstream metabolic outcomes.

Clinical research investigating Tesamorelin has focused on its influence on visceral adipose tissue (VAT) accumulation, particularly in populations where GH axis dysregulation contributes to central adiposity. Studies have reported measurable changes in adipose tissue distribution and improvements in lipid profiles in research subjects. Preclinical work has characterized its receptor binding kinetics, pulsatile GH release amplification, and downstream effects on IGF-1 levels. Research has also examined its potential relevance in cognitive aging models, with some studies investigating GH axis stimulation and neurological outcomes.

Tesamorelin is a frequently referenced GHRH analog in metabolic research, growth hormone axis studies, and lipodystrophy research. This 10mg lyophilized preparation is intended for preclinical research and in vitro studies examining GHRH receptor pharmacology and GH-mediated metabolic effects.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.